Apolipoprotein A-I (ApoA-I)

Cardiovascular

Advanced Lipid Markers

mg/dL

Apolipoprotein A-I (ApoA-I) is the main structural protein of HDL particles and the engine of reverse cholesterol transport, helping move cholesterol away from the artery wall. Because it reflects the functional capacity of HDL rather than just its cholesterol content, a preventive practice tracks ApoA-I as a more direct measure of the protective side of the lipid system.

What It Measures

Primary protein of HDL particles; anti-inflammatory, reverse cholesterol transport

Optimal vs. Lab Range

Longevity Optimal

>150 mg/dL

Target range for optimal health and longevity based on research.

Standard Lab

120–180 mg/dL (M), 140–200 (F)

Population-based reference range from standard labs.

Why It Matters

ApoA-I represents the machinery behind HDL's protective, anti-inflammatory role, so higher levels are generally favorable and low levels are associated with cardiovascular risk, metabolic syndrome, and familial HDL deficiency. Measured alongside ApoB, it enables the ApoB/ApoA-I ratio, which contrasts atherogenic particle burden against protective capacity and can sharpen cardiovascular risk assessment beyond a standard lipid panel. As with HDL itself, the relationship is not simply that more is always better, so ApoA-I is best interpreted in the context of the whole lipid and metabolic picture rather than maximized in isolation.

When Low

Cardiovascular risk, metabolic syndrome, familial HDL deficiency

When High

Generally protective when high

How to Optimize

The levers that support healthy HDL also support ApoA-I: regular aerobic exercise, an omega-3-sufficient whole-food dietary pattern, not smoking, and broader metabolic optimization. Some approaches such as niacin or moderate alcohol are discussed but remain controversial and should only be considered under physician guidance. Because ApoA-I reflects HDL function within the larger lipid system, it is best improved as part of overall cardiovascular and metabolic health. Targets and treatment are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Moderate evidence

Key Interventions

Exercise

omega-3

moderate alcohol (controversial)

niacin

Linked Compounds & Supplements

Omega-3

Niacin

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Annual

Reporting unit

mg/dL

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Apolipoprotein A-I (ApoA-I).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.